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Background: Tumor infiltrating immune cells can modulate cancer progression and are attractive 
therapeutic targets. We have previously identified a tumor microenvironment (TME) immune cell 
signature in diffuse large B-cell lymphoma (DLBCL), which contains genes for cytolytic factors, 
immune checkpoint molecules, T-cells and macrophages, and separates the patients into immune 
cell high and low or T-cell inflamed and non-inflamed subgroups (Autio et al., 2020). As 
macrophages and T-cells are key components of the TME, our aim was to characterize their 
phenotypes and relationships in the tumor tissue and associate the findings to clinical outcome in 
patients with DLBCL. 
Methods: We used multiplex immunohistochemistry, gene expression data, and unsupervised 
computational approaches to characterize tumor associated T-cell and macrophage (TAM) 
phenotypes in 178 samples from DLBCL patients. We correlated the immune cell constitution with 
clinical data, and validated the findings utilizing gene expression data from three independent 
DLBCL cohorts (Reddy et al., 2017, Schmitz et al., 2018, Chapuy et al., 2018) and in silico 
immunophenotyping with CIBERSORT. 
Results: The proportions of TAMs and infiltrating T-cells varied significantly between the patients. 
Unsupervised hierarchical clustering divided the samples into T-cell inflamed and non-inflamed 
subgroups. The T-cell inflamed phenotype was rich in other immune cell subtypes such as TAMs, 
natural killer (NK) cells, and regulatory T-cells, thus characterizing an immune hot phenotype. 
Apart from B-symptoms being more common in the patients with T-cell inflamed phenotype, 
clinical characteristics were equally distributed between the subgroups, and no association with 
survival was observed. However, when we divided the T-cell inflamed group further into subgroups 
according to the TAM content, we identified a T-cell high/macrophage low group, which was 
characterized by clinically less aggressive disease and better survival as compared to the T-cell 
high/macrophage high or T-cell low groups. Using in silico deconvolution analyses, we validated 
the T-cell high/macrophage low subgroup, and its association with less aggressive disease and 
survival in an external dataset comprising 496 patients (Reddy et al., 2017). The prognostic impact 
of T-cell high/macrophage low subgroup on survival was independent of the IPI and molecular 
subtype. Differential gene expression analyses identified a gene signature corresponding to the T-
cell high/macrophage low subgroup. This signature translated to better outcome, and was validated 
in two additional datasets (Schmitz et al. n=562, Chapuy et al. n=137). Finally, we studied the 
impact of immune checkpoint expressing TAMs on survival, and whether it differed between the T-
cell inflamed and T-cell non-inflamed subgroups. In particular, a high proportion of PD-L1+, 
TIM3+, and PD-L1+TIM3+CD163- macrophages associated with poor outcome, independent from 
the IPI and molecular subtype. Furthermore, the impact of these TAM subtypes on survival was 
evident only in the patients with T-cell inflamed phenotype. 
Conclusions: Our data demonstrate that the proportions of different immune cell phenotypes in the 
DLBCL TME are clinically meaningful, and suggest that the high T-cell/macrophage ratio predicts 
favorable survival in patients with DLBCL. 
 
